01:35 PM EDT, 05/10/2024 (MT Newswires) -- Iovance Biotherapeutics' ( IOVA ) "disciplined" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping minimize patient attrition, Truist Securities said in a note Friday.

The company reported having enrolled over 100 patients for treatment, which Truist described as solid.

"Based on our analysis, time from enrollment to receiving therapy (which is the billable, revenue-generating event) is taking longer than what was anticipated, but this is likely to improve as treatment centers and payors become more familiar," Truist Securities said, adding it expects more than 60 patients treated would contribute to the company's Q2 revenue.

Enrollment to infusion currently takes around three months, but this could be shortened to six to eight weeks as each authorized treatment center gains more experience in handling patients, the note said. Truist said the number of treatment centers is on track to reach about 50 by end of this month and 70 by year-end.

Truist maintained its buy rating on Iovance Biotherapeutics ( IOVA ) with a price target of $26.

Price: 10.76, Change: -2.69, Percent Change: -20.00